Skip to main content
Clinical Trials/CTIS2023-508560-29-00
CTIS2023-508560-29-00
Active, not recruiting
Phase 1

A randomised controlled trial of a moisturiser for treatment of dry skin in atopic dermatitis: effect on the skin barrier in adults with a history of eczema - CSCI-SKT-B1001

ACO Hud Nordic AB0 sites55 target enrollmentOctober 8, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Atopic dermatitis
Sponsor
ACO Hud Nordic AB
Enrollment
55
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 8, 2023
End Date
March 14, 2024
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Participants \= 18 years old, A history of atopic dermatitis according to UK working party criteria, Willing and able to provide informed consent

Exclusion Criteria

  • Substantial flare\-up of atopic dermatitis more than minimal (not manageable with moisturiser only) during ideally within the last 6 months, Eczema on the volar forearms, Participants with known or suspected allergies or contraindications to any of the IPs and AxMP ingredients, Participants unwilling to refrain from using prohibited medication including moisturisers (other than the IP, the AxMP and the standard soap for washing), Female participants who, according to the participant, is pregnant or breast\-feeding, or plans to become pregnant during the study, Participants judged by the investigator to be inappropriate for the trial., Any serious current medical condition which, in the opinion of the investigator, may interfere with the evaluation of the results or may be contraindicated by the use of the investigational products, Atopic dermatitis targeted systemic therapy as well as any other immunomodulatory systemic therapy over more than 8 days in past 12 months (glucocorticoids, biologicals, cyclosporines, JAK inhibitors, off\-label azathioprine, mycophenolate\-mofetil, alitretionin, photo therapy), Any treatment with TCS' or other established topical treatment for AD within the last 6 months prior screening and throughout the study. Except the two allowed corticosteroids for treatment of flare\-up during the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials